Searchable abstracts of presentations at key conferences in endocrinology

ea0029p829 | Endocrine tumours and neoplasia | ICEECE2012

Enhanced antitumor efficacy of fructose conjugated-gefitinib on lung cancer cell lines in vitro and in vivo

Hui H. , Zhang S. , Ding W. , Li J. , Zhao X. , Zuo M. , Wang X. , Gu W. , Pandol S. , Go V.

Cancer cells have shown an overexpressed fructose transporter GLUT5 and preferential utilization of fructose as compared to glucose, implicating that a fructose-based analogue would be a useful target for diagnosis and treatment of cancer. We have successfully synthesized the fructose conjugated-gefitinib compounds {N-[4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)-7-methoxy-quinazolin-6-yl]-4- [N-methyl-N-(1-deoxy-1-fructosyl)]aminobutanamide}, and examined its antitumor effic...

ea0007p47 | Diabetes, metabolism and cardiovascular | BES2004

A novel non-steroidal inhibitor of 11beta-hydroxysteroid dehydrogenase type 1 improves features of metabolic syndrome in murine disease models

Thieringer R , Balkovec J , Chen H , Frazier E , Le Grand C , Li Z , Metzger J , Mundt S , Nunes C , Strowski M , Olson S , Robertson N , Strack A , Schaeffer J , Wright S , Zhang B , Hermanowski-Votska A

Chronic exposure to elevated circulating glucocorticoids can lead to metabolic changes, which resemble those observed in Metabolic Syndrome. Features of the Metabolic Syndrome can be reversed by lowering systemic glucocorticoid levels or by treatment with a glucocorticoid receptor antagonist. At the intracellular level, exposure to glucocorticoids is regulated by two distinct 11beta-hydroxysteroid dehydrogenases, 11beta-HSD type 1 and type 2. 11beta-HSD1 predominantly acts as ...